Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

52.78 +2.31 (+4.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 879,866
Open 50.16
Bid (Size) 52.00 (2)
Ask (Size) 53.25 (1)
Prev. Close 50.47
Today's Range 50.00 - 53.19
52wk Range 38.94 - 86.95
Shares Outstanding 78,294,139
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace

Performance

YTD
+28.73%
+28.73%
1 Month
+34.68%
+34.68%
3 Month
-2.78%
-2.78%
6 Month
-29.63%
-29.63%
1 Year
-10.18%
-10.18%

More News

Read More
3 Gene Editing Stocks With the Best Long-Term Potential
Via InvestorPlace
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Via The Motley Fool
3 Smart Stocks to Buy if a Recession Is on the Way
Via The Motley Fool
CRISPR Therapeutics Stock: Bull vs. Bear
Via The Motley Fool
5 Reasons to Buy Vertex Pharmaceuticals Now
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
Expert Ratings for CRISPR Therapeutics
Via Benzinga
7 Biotech Stocks That Will Make You Rich in 10 Years
Via InvestorPlace
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
Via InvestorPlace
2 Stocks Down More Than 25% to Buy Right Now
Via The Motley Fool
5 Potentially Explosive Stocks to Buy in 2023
Via The Motley Fool
More Likely to 5X First: CRISPR Therapeutics vs. InMode
Via The Motley Fool
2 Growth Stocks You May Regret not Buying Right Now
Via The Motley Fool
Can Cathie Wood Bounce Back in 2023?
Via The Motley Fool
2 Supercharged Stocks to Buy Right Now That Could Soar in 2023
Via The Motley Fool
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
Via The Motley Fool
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Via Benzinga
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over Time
Via The Motley Fool
3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street
Via The Motley Fool
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.